Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SLC8A1 | P32418 | 6/20 | 0.34 |
| ▸ | ATP4A | P20648 | 1/20 | 0.34 |
| ▸ | ATP4B | P51164 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 3/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6019450 | 0.92 | DHODH (0.36) | RAB9ASLC8A1ATP4AATP4BDHODH | |
| SCHEMBL4663178 | 0.92 | DHODH (0.36) | RAB9ASLC8A1ATP4AATP4BDHODH | |
| SCHEMBL6020045 | 0.92 | DHODH (0.36) | RAB9ASLC8A1ATP4AATP4BDHODH | |
| SCHEMBL5506543 | 0.90 | RAB9A (0.35) | RAB9ASLC8A1ATP4AATP4BDHODH | |
| SCHEMBL5506550 | 0.90 | RAB9A (0.35) | RAB9ASLC8A1ATP4AATP4BDHODH | |
| SCHEMBL4664616 | 0.88 | RIPK1 (0.36) | RAB9ASLC8A1ATP4AATP4BDHODH | |
| SCHEMBL4662902 | 0.88 | RIPK1 (0.36) | RAB9ASLC8A1ATP4AATP4BDHODH | |
| SCHEMBL4664869 | 0.88 | MEN1 (0.39) | RAB9ASLC8A1 | |
| SCHEMBL5116463 | 0.88 | RAB9A (0.36) | RAB9ASLC8A1ATP4AATP4B | |
| SCHEMBL4664655 | 0.88 | RAB9A (0.36) | RAB9ASLC8A1ATP4AATP4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | claimed |
| US-20080113963-A1 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | disclosed |
| US-20060194968-A1 | Cyclic benizimidazoles | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194968-A1 | Cyclic benizimidazoles | VIP, SI, GIPR | RAB9A 4475/4885SLC8A1 3053/4885ATP4A 417/4885 |
| US-20080113963-A1 | Cyclic benzimidazoles | VIP, GIPR, SI | RAB9A 2004/4885SLC8A1 3552/4885ATP4A 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.